ProShare Advisors
CARM

ProShare Advisors’s Carisma Therapeutics CARM Stock Holding History

ProShare Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-839
Closed -$7K – 1857
2022
Q3 		$7K Buy
839
+62
+8% +$844 ﹤0.01% 1739
2022
Q2 		$13K Sell
777
-2,142
-73% -$24.5K ﹤0.01% 1781
2022
Q1 		$34K Sell
2,919
-684
-19% -$9.55K ﹤0.01% 2142
2021
Q4 		$59K Buy
3,603
+2,335
+184% +$47K ﹤0.01% 2263
2021
Q3 		$20K Sell
1,268
-950
-43% -$45.6K ﹤0.01% 1999
2021
Q2 		$205K Buy
+2,218
New +$141K ﹤0.01% 2130

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BWA
Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's CARM Position: Q4 2022 in Review

ProShare Advisors sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 839 shares — an estimated $7K sold.

ProShare Advisors first reported a position in CARM in Q2 2021 and held it in 6 quarters. The position peaked at $205K in Q2 2021. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

  • ProShare Advisors reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ProShare Advisors sold 839 Carisma Therapeutics shares in Q4 2022, an estimated $7K.
  • ProShare Advisors first reported a position in Carisma Therapeutics in Q2 2021 and held it in 6 quarters.
  • ProShare Advisors's Carisma Therapeutics position peaked at $205K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.